BioVector? pHFMDHZ-A Foot-and-Mouth Disease Virus DNA Vaccine Expression Vector / pHFMDHZ-A 口蹄疫病毒DNA疫苗與重組高效表達(dá)載體

一 產(chǎn)品基本信息與分子生物學(xué)背景

• 載體名稱(chēng)：pHFMDHZ-A。

• 載體分類(lèi)：哺乳動(dòng)物細(xì)胞真核表達(dá)質(zhì)粒 / 口蹄疫病毒（FMDV）多表位重組DNA疫苗載體。

• 質(zhì)粒大小：約 5.5 - 6.2 kb（依據(jù)克隆的 FMDV 特異性抗原表位或全長(zhǎng) $VP1$ 基因片段的血清型微調(diào)）。

• 骨架源起與設(shè)計(jì)背景（獸醫(yī)病毒學(xué)疫苗標(biāo)盤(pán)）：

  pHFMDHZ-A 是一款在獸醫(yī)病毒學(xué)、現(xiàn)代畜牧業(yè)傳染病防控以及合成生物學(xué)疫苗工程中廣泛應(yīng)用的專(zhuān)用真核表達(dá)質(zhì)粒。其核心骨架主要基于強(qiáng)力的真核表達(dá)體系（通常派生自帶有高級(jí)順式促表達(dá)元件的 pcDNA 系列或 pVAX1 疫苗標(biāo)準(zhǔn)底盤(pán)），專(zhuān)為針對(duì)口蹄疫病毒（Foot-and-Mouth Disease Virus, FMDV）的 A 型（或融合 O 型等中和表位）進(jìn)行高水平抗原遞呈而設(shè)計(jì)。

  傳統(tǒng)的滅活口蹄疫疫苗存在生產(chǎn)過(guò)程中病毒泄漏、熱穩(wěn)定性差以及無(wú)法區(qū)分免疫動(dòng)物與自然感染動(dòng)物（DIVA 缺陷）等安全隱患。pHFMDHZ-A 重組質(zhì)粒通過(guò)在宿主（如豬、牛、羊等偶蹄動(dòng)物）骨骼肌細(xì)胞中直接轉(zhuǎn)錄并翻譯出 FMDV 的核心中和抗原（如結(jié)構(gòu)蛋白 $VP1$ 或其連續(xù)多表位多肽 Poly-epitope），誘導(dǎo)機(jī)體產(chǎn)生強(qiáng)烈的體液免疫與細(xì)胞免疫應(yīng)答，是研發(fā)新型基因工程核酸疫苗、DNA 載體主次免疫策略（Prime-boost strategy）的經(jīng)典骨架。

• 核心順式作用元件與圖譜特征：

  • 人巨細(xì)胞病毒超強(qiáng)啟動(dòng)子（CMV Promoter）：驅(qū)動(dòng)下游 FMDV 抗原基因在哺乳動(dòng)物及家畜骨骼肌/樹(shù)突狀細(xì)胞中進(jìn)行不依賴(lài)宿主細(xì)胞周期的、極其強(qiáng)勁的結(jié)構(gòu)性轉(zhuǎn)錄。

  • FMDV A型核心抗原編碼夾層（FMDV-A Antigen Cassette）：多克隆位點(diǎn)（MCS）中已原裝嵌入或保留用于插入口蹄疫病毒 A 型毒株的核心免疫原片段。它通常包含 $VP1$ 關(guān)鍵環(huán)區(qū)（G-H Loop）的 B 細(xì)胞中和表位與特定的 T 細(xì)胞輔助表位串聯(lián)體。

  • 真核高效翻譯與加尾元件：配置了優(yōu)化的 Kozak 序列（確保核糖體精準(zhǔn)錨定并啟動(dòng)翻譯）以及典型的牛生長(zhǎng)激素聚腺苷酸信號(hào)（BGH polyA），可最大化提升 mRNA 在家畜胞內(nèi)的穩(wěn)定性和生存期。

  • 大腸桿菌復(fù)制與抗性（符合國(guó)際疫苗安全標(biāo)準(zhǔn)）：含有 pUC ori 以及 卡那霉素抗性基因（$Kan^R$）（嚴(yán)禁使用氨芐青霉素抗性，以完全符合國(guó)際獸藥組織和 FDA 關(guān)于動(dòng)物 DNA 疫苗中不得引入內(nèi)酰胺類(lèi)抗生素標(biāo)記的安全紅線(xiàn)），專(zhuān)用于前期在 E. coli 中進(jìn)行大規(guī)模、高密度的發(fā)酵工程純化。

二 核心科研價(jià)值與獸醫(yī)臨床轉(zhuǎn)化應(yīng)用

pHFMDHZ-A 質(zhì)粒在現(xiàn)代動(dòng)物醫(yī)學(xué)、新型核酸免疫及重大傳染病阻斷中占據(jù)核心一席：

1. 家畜口蹄疫 A 型/多價(jià)重組 DNA 疫苗效能評(píng)估：

   利用 pHFMDHZ-A 載體直接肌肉注射或通過(guò)基因槍?zhuān)℅ene gun）導(dǎo)入豬、牛等靶向目標(biāo)宿主。質(zhì)粒被肌細(xì)胞或抗原遞呈細(xì)胞（APC）吞噬后，在體內(nèi)持續(xù)合成 FMDV 病毒樣抗原結(jié)構(gòu)，刺激 T、B 淋巴細(xì)胞全面激活。通過(guò)檢測(cè)動(dòng)物血清中的中和抗體效價(jià)（Neutralizing antibody titer）以及 IFN-$\gamma$ 等細(xì)胞因子的釋放水平，評(píng)估該 DNA 疫苗在面臨強(qiáng)毒株攻擊時(shí)的真實(shí)保護(hù)率（Protection rate）。

2. 多表位串聯(lián)與新型佐劑（Adjuvant）配伍設(shè)計(jì)：

   科研人員常利用該骨架的 MCS 區(qū)域，將 FMDV 的核心中和表位與重組免疫佐劑基因（如家畜 IL-2、IL-6 或粒細(xì)胞-巨噬細(xì)胞集落刺激因子 GM-CSF）并排串聯(lián)共表達(dá)。這種一體化的分子設(shè)計(jì)能顯著突破傳統(tǒng) DNA 疫苗免疫原性偏弱的瓶頸，成倍提升家畜產(chǎn)生特異性 IgG 抗體的速度和豐度。

3. 反向遺傳學(xué)與病毒樣顆粒（VLPs）體外組裝：

   通過(guò)將 FMDV 的主要結(jié)構(gòu)蛋白（$VP0$, $VP3$, $VP1$）聯(lián)合組裝入 pHFMDHZ-A 衍生系統(tǒng)中，在哺乳動(dòng)物細(xì)胞（如 BHK-21）內(nèi)共表達(dá)，可促使這些衣殼蛋白在胞內(nèi)自組裝形成不含病毒核酸、卻具有高度天然空間構(gòu)象的病毒樣顆粒（Virus-Like Particles, VLPs）。這為開(kāi)發(fā)絕對(duì)安全、無(wú)傳染性、且能完美分辯“免疫與感染”的新一代口蹄疫亞單位工程疫苗提供了精密的反應(yīng)底盤(pán)。

三 實(shí)驗(yàn)室大腸克隆、發(fā)酵純化、哺乳動(dòng)物細(xì)胞轉(zhuǎn)染與體內(nèi)免疫質(zhì)控標(biāo)準(zhǔn)步驟

1. 質(zhì)粒在大腸桿菌（E. coli）中的高密度發(fā)酵與無(wú)毒純化（制備疫苗級(jí) DNA）

• 轉(zhuǎn)化與平板篩選：將環(huán)狀 pHFMDHZ-A 質(zhì)粒轉(zhuǎn)化入常規(guī)大腸桿菌高產(chǎn)量菌株（如 DH5$\alpha$ 或 JM109）感受態(tài)中。均勻涂布于含有 50 $\mu$g/mL 卡那霉素（Kanamycin）的常規(guī) LB 固體平板上，37 ℃ 培養(yǎng)過(guò)夜。

• 高質(zhì)純化（絕對(duì)關(guān)鍵點(diǎn)：去除內(nèi)毒素）：

  由于該質(zhì)粒最終通常需要用于動(dòng)物活體注射或哺乳動(dòng)物原代細(xì)胞轉(zhuǎn)染，普通的普通質(zhì)粒提取試劑盒無(wú)法滿(mǎn)足要求。必須使用去內(nèi)毒素重組質(zhì)粒大抽試劑盒（Endotoxin-free Plasmid Maxiprep Kit）。純化出的疫苗級(jí) DNA 必須滿(mǎn)足：濃度 $\ge 1.0\text{ mg/mL}$，純度 $OD_{260}/OD_{280} = 1.80 - 1.90$，且內(nèi)毒素（Endotoxin）含量必須 $\lt 0.1\text{ EU/}\mu\text{g}$。內(nèi)毒素過(guò)高會(huì)在動(dòng)物體內(nèi)引發(fā)強(qiáng)烈的非特異性發(fā)熱、炎癥反應(yīng)，甚至導(dǎo)致轉(zhuǎn)染細(xì)胞大面積毒性凋亡，從而徹底掩蓋或破壞 DNA 疫苗的真實(shí)免疫效果。

2. 哺乳動(dòng)物細(xì)胞（如 BHK-21 / HEK-21）的體外效能驗(yàn)證轉(zhuǎn)染操作

在進(jìn)行活體動(dòng)物免疫前，必須先在體外貼壁細(xì)胞系（經(jīng)典靶向?yàn)閭}(cāng)鼠腎細(xì)胞 BHK-21 或人腎上皮細(xì)胞 HEK-293T）中驗(yàn)證 pHFMDHZ-A 是否能夠成功轉(zhuǎn)錄并高效表達(dá)出正確的 FMDV 抗原蛋白。

1. 鋪板與細(xì)胞狀態(tài)質(zhì)控：

   轉(zhuǎn)染前一天，將 BHK-21 細(xì)胞接種于 6 孔板中，使用含有 10% 優(yōu)質(zhì)胎牛血清的高糖 DMEM 完全培養(yǎng)基培養(yǎng)，待轉(zhuǎn)染當(dāng)天的細(xì)胞匯合度（Confluency）達(dá)到 70% - 80% 且處于對(duì)數(shù)生長(zhǎng)最旺盛期。

2. 重組轉(zhuǎn)染復(fù)合物配制（以脂質(zhì)體 Lipofectamine 3000 為例）：

   • A管：吸取 125 $\mu$L 無(wú)血清 Opti-MEM 培養(yǎng)基，加入 2.5 - 4.0 $\mu$g 的去內(nèi)毒素 pHFMDHZ-A 質(zhì)粒 DNA，再加入 5 $\mu$L P3000 試劑，輕柔混勻。

   • B管：吸取 125 $\mu$L 無(wú)血清 Opti-MEM 培養(yǎng)基，加入 5 - 7.5 $\mu$L Lipofectamine 3000 轉(zhuǎn)染試劑，輕柔混勻。

   • 復(fù)合孵育：將 A 管溶液全量倒入 B 管中，極其輕柔地吹打 2 次，室溫下靜置孵育 10 - 15 分鐘，使其充分包裹組裝成帶正電荷的納米級(jí)脂質(zhì)體-DNA 復(fù)合物。

3. 加樣與溫和轉(zhuǎn)染：

   • 將 250 $\mu$L 的復(fù)合物均勻逐滴滴加到長(zhǎng)有 BHK-21 細(xì)胞的 6 孔板孔中，十字搖勻。

   • 放入 37 ℃、5% $CO_2$ 的無(wú)菌孵箱中。轉(zhuǎn)染 4 - 6 小時(shí)后，為了最大化減輕轉(zhuǎn)染試劑對(duì)細(xì)胞膜的剪切毒性，建議全量更換為新鮮的含 2% FBS 的 DMEM 維持培養(yǎng)基，繼續(xù)暗培養(yǎng) 24 - 48 小時(shí)。

3. FMDV 抗原體外表達(dá)的檢測(cè)與質(zhì)量評(píng)估

轉(zhuǎn)染 48 小時(shí)后，收集細(xì)胞樣品以確證重組抗原的合成質(zhì)量：

• 胞內(nèi)表達(dá)與空間構(gòu)象驗(yàn)證（免疫熒光間接法 IFA）：

  吸除培養(yǎng)基，用 PBS 洗滌細(xì)胞 2 次，使用 4% 對(duì)聚甲醛固定細(xì)胞 15 分鐘。使用 0.1% Triton X-100 透膜后，加入特異性的抗 FMDV-A 型 VP1 單克隆抗體（或偶蹄動(dòng)物康復(fù)期陽(yáng)性血清）作為一抗，4 ℃ 孵育過(guò)夜。次日洗凈后加入帶有熒光標(biāo)記（如 FITC，發(fā)射綠光）的二抗。在熒光顯微鏡下觀(guān)察，若胞質(zhì)內(nèi)暴射出強(qiáng)烈的點(diǎn)狀或彌漫性綠色熒光，證實(shí) pHFMDHZ-A 具備完美的體外轉(zhuǎn)錄與正確的空間折疊表型。

• 分子量與定量檢測(cè)（Western Blot）：

  使用 RIPA 裂解液收集細(xì)胞總蛋白，進(jìn)行 SDS-PAGE 電泳并轉(zhuǎn)移至 PVDF 膜上。利用特異性抗體進(jìn)行顯色，確證在預(yù)期分子量位置（如單體 VP1 約 24-26 kDa，或多表位融合肽對(duì)應(yīng)分子量）出現(xiàn)清晰、均一、無(wú)無(wú)雜帶的特定目標(biāo)條帶。

4. 動(dòng)物活體（In vivo）免疫注射與長(zhǎng)期儲(chǔ)存標(biāo)準(zhǔn)

1. 肌肉注射免疫規(guī)范：

   體外質(zhì)控達(dá)標(biāo)后，將去內(nèi)毒素的 pHFMDHZ-A 質(zhì)粒用無(wú)菌生理鹽水（PBS）稀釋至工作濃度（如 500 $\mu$g - 1000 $\mu$g / 劑）。選擇健康、經(jīng)檢測(cè) FMDV 母源抗體陰性的實(shí)驗(yàn)偶蹄動(dòng)物（如小口徑 Beagle 犬作為安全毒性模型，或直接用于靶向幼豬、羊）。于動(dòng)物后肢股四頭肌或頸部進(jìn)行深部肌肉注射（Intramuscular injection）。根據(jù)免疫策略，通常在第 0 周進(jìn)行初免（Prime），第 3-4 周進(jìn)行相同劑量的加強(qiáng)免疫（Boost），并在各個(gè)節(jié)點(diǎn)采血分離血清，進(jìn)行液相阻斷 ELISA（LPBE）或微量中和試驗(yàn)，評(píng)估抗體陽(yáng)轉(zhuǎn)率。

2. 質(zhì)粒長(zhǎng)期保存標(biāo)準(zhǔn)：

   • 短期存放：純化好的高純度 pHFMDHZ-A 質(zhì)粒溶解于無(wú)菌 TE 緩沖液或超純水中，4 ℃ 下可穩(wěn)定存放 2-3 個(gè)月。

   • 長(zhǎng)期鎖死存放：分裝成小體積（避免反復(fù)凍融），置于 -20 ℃ 或 -80 ℃ 超低溫冰箱中鎖死保存。在無(wú)菌且避免核酸酶污染的前提下，DNA 質(zhì)粒在超低溫下可穩(wěn)定保存數(shù)年而其生物學(xué)超螺旋結(jié)構(gòu)（Supercoiled form）和轉(zhuǎn)染活性不發(fā)生降解。

Part 2 English Section

I General Information and Molecular Biological Background

• Vector Name: pHFMDHZ-A.

• Vector Classification: Mammalian 真核 expression vehicle / Recombinant poly-epitope DNA vaccine framework targeting Foot-and-Mouth Disease Virus (FMDV).

• Plasmid Size Scale: Approximately 5.5 - 6.2 kb (subject to minor variations configured to specific regional FMDV serotype antigens or length variants of the $VP1$ gene sequence).

• Backbone Origin and Veterinary Virology Context:

  The pHFMDHZ-A expression vector stands as a highly specialized genetic platform optimized for veterinary virology, livestock infectious disease counter-measures, and synthetic biology vaccine development. Its baseline framework is standardly constructed upon a robust mammalian expression engine (typically derived from classic optimized elements like the pcDNA or regulatory-approved pVAX1 DNA vaccine base backbones), precision-engineered to drive high-capacity expression of neutralizable antigens representing Foot-and-Mouth Disease Virus (FMDV) Serotype A (or engineered multivalent combination configurations).

  Traditional inactivated FMDV vaccines pose substantial biosecurity risks, including potential viral leakage during industrial manufacturing, low thermal stability, and an inability to distinguish vaccinated animals from naturally infected herds (lacking DIVA capability). The pHFMDHZ-A recombinant construct bypasses these constraints by delivering the targeted DNA directly into the skeletal muscle or dendritic cells of cloven-hoofed hosts (e.g., swine, cattle, sheep). This direct delivery prompts in vivo transcription and translation of targeted structural proteins (such as the envelope determinant $VP1$ or interconnected multi-epitope string domains), activating both robust humoral and cell-mediated immune responses. It serves as a gold-standard vehicle for evaluating nucleic acid therapeutics and designing prime-boost viral clearance strategies.

• Core Cis-Acting Elements and Map Characterization:

  • Human Cytomegalovirus Immediate-Early Promoter (CMV Promoter): Forces aggressive, transcription-factor independent mRNA synthesis of the downstream FMDV antigen payload inside mammalian structural muscle arrays and antigen-presenting cell environments.

  • FMDV Serotype A Antigen Cassette: The Multiple Cloning Site (MCS) is standardly loaded with (or engineered to accept) core immunogenic matrices derived from Serotype A isolates. This configuration standardly targets the highly variable G-H loop region of the $VP1$ protein, containing principal neutralizable B-cell epitopes linked sequentially with localized helper T-cell motifs.

  • High-Efficiency Eukaryotic Translational Machinery: Outfitted with a highly optimized Kozak consensus sequence immediately preceding the translation initiation codon to ensure precise ribosome docking, paired with a downstream Bovine Growth Hormone Polyadenylation Signal (BGH polyA) to augment transcription transcript stability and functional half-life within host tissues.

  • E. coli Propagation Assembly (Strict Regulatory Standard Alignment): Formulated with a standard pUC replication origin and a functional Kanamycin resistance gene ($Kan^R$). The integration of an Ampicillin marker is strictly avoided to comply with international regulatory mandates (FDA and WOAH) that prohibit beta-lactam selection markers in livestock DNA vaccine configurations. This design enables high-density industrial fermentation and high-purity vector isolation within Escherichia coli validation systems.

II Strategic Research Value and Veterinary Translational Applications

The pHFMDHZ-A platform serves as a critical preclinical blueprint for evaluating innovative veterinary biologics and exploring anti-viral defense networks:

1. Preclinical Profiling of Serotype-Specific Livestock DNA Vaccines:

   By injecting pHFMDHZ-A directly via intramuscular delivery or high-velocity gene gun platforms into targeted livestock models (e.g., swine or cattle), host structural arrays internalize the vector. The host cells subsequently process and present the synthesized FMDV antigen complexes to T and B lymphocytes. Measuring neutralizing antibody titers and monitoring targeted cytokine release (such as IFN-$\gamma$) provides a clear assessment of real-time protection efficiency against viral challenge.

2. Design Arrays for Poly-Epitope Concatenation and Molecular Adjuvants:

   Investigators standardly exploit the multi-cloning configuration to assemble chimeric expressions fusing targeted FMDV structural segments in tandem with molecular host adjuvants (e.g., porcine or bovine IL-2, IL-6, or GM-CSF). This integrated design overcomes the low immunogenicity limitations typical of standard legacy naked DNA vaccines, significantly increasing IgG antibody titers and systemic cellular memory responses.

3. Reverse Genetics and In Vitro Assembly of Virus-Like Particles (VLPs):

   Co-delivering the baseline structural proteins of FMDV ($VP0$, $VP3$, $VP1$) using pHFMDHZ-A derived multi-expression systems into continuous mammalian cell lines (e.g., BHK-21) enables the intracellular self-assembly of empty Virus-Like Particles (VLPs). These macromolecular arrays accurately mimic the native spatial conformation of the wild-type viral capsid but lack infectious viral nucleic acids, establishing a safe, non-replicative sub-unit architecture that supports accurate DIVA diagnostics.

III Laboratory Propagation, Endotoxin-Free Extraction, Transfection, and Immunological Validation Protocols

1. High-Density E. coli Fermentation and Endotoxin-Free Vector Processing

• Transformation Sequence: Introduce the circular pHFMDHZ-A vector into standard high-yield cloning E. coli cells (e.g., DH5$\alpha$ or JM109 competent arrays). Uniformly spread the transformation mixture onto solid selective LB agar plates supplemented with 50 $\mu$g/mL Kanamycin and incubate at 37 °C overnight.

• Endotoxin-Free Vector Isolation (Critical Safety Metric):

  Because this vector is intended for direct in vivo animal inoculations or sensitive primary cell transfections, standard industrial miniprep extraction mechanics are insufficient. Investigators must use specialized Endotoxin-Free Plasmid Maxiprep kits. The purified vaccine-grade DNA preparation must achieve a concentration of $\ge 1.0\text{ mg/mL}$, a clean purity index ($OD_{260}/OD_{280} = 1.80 - 1.90$), and an endotoxin payload threshold strictly beneath 0.1 EU/$\mu$g. Elevated endotoxin contamination triggers severe non-specific inflammatory shock, systemic pyrexia, and localized cellular apoptosis in recipient animals, compromising the validity of the vaccine evaluation.

2. In Vitro Validation via High-Efficiency Transfection of BHK-21 Cell Lines

Before initializing large-scale in vivo animal trials, the transcriptional fidelity and translation efficiency of pHFMDHZ-A must be verified in vitro using continuous susceptible cell lines, such as Baby Hamster Kidney cells (BHK-21) or human embryonic kidney lines (HEK-293T).

1. Monolayer Seeding and Quality Metrics:

   Seeding BHK-21 cells into 6-well plate configurations 24 hours prior to transfection using high-glucose DMEM complete medium fortified with 10% premium FBS. The cell layer must reach 70% - 80% confluency and remain in log-phase growth at the time of transfection.

2. Formulating Recombinant Transfection Complexes (Lipofectamine 3000 Protocol):

   • Tube A: Combine 125 $\mu$L of serum-free Opti-MEM reduced-serum matrix with 2.5 - 4.0 $\mu$g of endotoxin-free pHFMDHZ-A plasmid DNA; add 5 $\mu$L of P3000 reagent and mix gently.

   • Tube B: Combine 125 $\mu$L of serum-free Opti-MEM matrix with 5 - 7.5 $\mu$L of Lipofectamine 3000 transfection reagent and mix gently.

   • Complex Assembly: Transfer the contents of Tube A directly into Tube B. Mix using gentle pipetting and incubate statically at room temperature for 10 - 15 minutes to permit the assembly of cationic lipid-DNA liposomal nanoparticles.

3. Transfection Execution:

   • Add the 250 $\mu$L liposomal complex solution dropwise across the BHK-21 monolayer and rock the plate in a cross pattern to ensure even distribution.

   • Return the plates to the sterile incubator calibrated to 37 °C with 5% $CO_2$. To minimize liposomal membrane toxicity, aspirate the transfection matrix 4 - 6 hours post-application and replace with fresh maintenance DMEM supplemented with 2% FBS. Incubate for an additional 24 - 48 hours.

3. In Vitro FMDV Antigen Tracking and Expression Metrics

Following 48 hours of incubation, harvest the cell matrices to evaluate recombinant protein expression:

• Intracellular Spatial Mapping (Indirect Immunofluorescence Assay - IFA):

  Aspirate the growth fluid, wash twice with sterile PBS, and fix the cell sheet with 4% paraformaldehyde for 15 minutes. Permeabilize cell membranes using 0.1% Triton X-100, then apply an anti-FMDV Serotype A VP1 monoclonal antibody (or hyper-immune convalescent livestock serum) as the primary detection antibody, incubating at 4 °C overnight. Wash thoroughly, then apply a fluorophore-conjugated secondary detection antibody (e.g., FITC, emitting green light). Under a fluorescence microscope, robust punctate or diffuse green fluorescence localized within the cytoplasm confirms target antigen expression and proper protein folding.

• Molecular Weight Verification (Western Blotting Array):

  Lyse the monolayers using RIPA lysis buffer and isolate total cellular protein. Resolve the samples via SDS-PAGE and transfer to a PVDF membrane. Probing with the specific primary antibody should reveal a distinct band at the expected molecular weight (e.g., monomeric VP1 clocks around 24-26 kDa), confirming a clean expression profile free of non-specific degradation products.

4. In Vivo Livestock Inoculation Steps and Cryopreservation Parameters

1. Intramuscular Immunization Protocol:

   Following successful in vitro validation, dilute the endotoxin-free pHFMDHZ-A plasmid matrix in sterile saline (PBS) to a target working dose (typically 500 $\mu$g - 1000 $\mu$g per injection). Select healthy, FMDV-maternal antibody-negative target livestock (such as young swine or sheep). Deliver the dose via deep intramuscular injection into the quadriceps or the neck muscle layers. Execute a prime-boost schedule, applying an identical booster dose 3 - 4 weeks post-priming. Collect regular blood samples to isolate serum and monitor antibody seroconversion metrics via liquid-blocking ELISA (LPBE) or micro-neutralization assays.

2. Long-Term Vector Cryopreservation Standards:

   • Short-Term Maintenance: Store purified high-purity pHFMDHZ-A plasmid dissolved in sterile TE buffer or ultra-pure water at 4 °C for 2 - 3 months.

   • Long-Term Cryopreservation: Aliquot the plasmid into small single-use working volumes to prevent repeated freeze-thaw degradation. Store the vials inside an ultra-low freezer calibrated to -20 °C or -80 °C. Under sterile conditions free of nucleating contamination, the supercoiled plasmid structure and functional transfection velocity remain fully stable for several years.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話(huà):400-800-2947

工作QQ/微信同號(hào):1843439339

網(wǎng)址http://www.nedfriskphoto.com